Pyxis Oncology (NASDAQ:PYXS) Trading Down 4.7% – Time to Sell?

Pyxis Oncology, Inc. (NASDAQ:PYXS)’s stock price fell 4.7% during mid-day trading on Monday . The stock traded as low as $1.21 and last traded at $1.22. 720,268 shares were traded during trading, an increase of 19% from the average session volume of 606,162 shares. The stock had previously closed at $1.28.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. William Blair downgraded Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 target price (down previously from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Stephens assumed coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective (down from $7.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $9.20.

Pyxis Oncology Stock Performance

The stock has a 50 day moving average price of $1.51 and a 200 day moving average price of $2.67. The company has a market capitalization of $72.55 million, a P/E ratio of -1.18 and a beta of 1.06.

Institutional Trading of Pyxis Oncology

Several hedge funds have recently added to or reduced their stakes in PYXS. ProShare Advisors LLC purchased a new stake in shares of Pyxis Oncology during the 4th quarter worth approximately $26,000. Caption Management LLC purchased a new position in Pyxis Oncology in the fourth quarter valued at approximately $35,000. Ameriprise Financial Inc. bought a new position in Pyxis Oncology during the fourth quarter valued at $35,000. Commonwealth Equity Services LLC increased its position in Pyxis Oncology by 61.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock worth $41,000 after buying an additional 10,000 shares during the last quarter. Finally, Graham Capital Management L.P. bought a new stake in shares of Pyxis Oncology in the fourth quarter valued at $47,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.